ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C1327287 | Prevention of degradation of mRNA molecules. In the absence of compensating changes in other processes, the slowing of mRNA degradation can result in an overall increase in the population of active mRNA molecules. [GOC:jid] | null | mRNA stabilization |
C0001056 | The N-acetyl derivative of glucosamine. | D-GlcNAc|N-Acetylglucosamine (substance)|D-Glucose, 2-(acetylamino)-2-deoxy-|acetylglucosamine|N-Acetylchitosamine|n-acetyl glucosamine|Acetylglucosamine|N-Acetylglucosamine|N acetylglucosamine|N-acetylglucosamine|2 Acetamido 2 Deoxyglucose|N Acetyl D Glucosamine|2-Acetamido-2-deoxy-D-glucose|2-Acetamido-2-Deoxy-D-Glucose|N-Acetyl Glucosamine D-|2 Acetamido 2 Deoxy D Glucose|aldehydo-N-acetyl-D-glucosamine|n-Acetyl glucosamine|N-ACETYL-.ALPHA.-D-GLUCOSAMINE|n-acetylglucosamine|2-Acetamido-2-Deoxyglucose|N-Acetyl-D-Glucosamine|N-Acetyl-D-glucosamine|N-ACETYLGLUCOSAMINE | acetylglucosamine |
C0010724 | Cytidine 5'-(trihydrogen diphosphate). A cytosine nucleotide containing two phosphate groups esterified to the sugar moiety. Synonyms: CRPP; cytidine pyrophosphate. | Cytidine diphosphate|cytidine diphosphate (CDP)|Cytidine diphosphate (CDP)|Cytidine diphosphate (substance)|cytidine diphosphate|Cytidine Diphosphate|cdp|CDP (cytidine diphosphate)|Cytidine 5'-(trihydrogen diphosphate)|Diphosphate, Cytidine|CDP | Cytidine Diphosphate |
C0278107 | null | ejaculations pain|ejaculation pain|pain ejaculation|ejaculation painful|EJACULATION PAIN|Painful ejaculation (finding)|Painful ejaculation|painful ejaculation | Painful ejaculation |
C0026056 | A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. | Midazolamum|Product containing midazolam (medicinal product)|4H-Imidazo(1,5-a)(1,4)benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl-|Midazolam-containing product|Midazolam|8-Chloro-6-(2-fluorophenyl)-1-Methyl- 4H- Imidazo(1,5a)(1,4)Benzodiazepine|Midazolam (substance)|midazolam|MIDAZOLAM | midazolam |
C0128897 | A chemokine that is a chemoattractant for MONOCYTES and may also cause cellular activation of specific functions related to host defense. It is produced by LEUKOCYTES of both monocyte and lymphocyte lineage and by FIBROBLASTS during tissue injury. It has specificity for CCR2 RECEPTORS. | Chemoattractant Protein-1, Monocyte|Chemotactic Protein-1, Monocyte|Monocyte Chemoattractant Protein-1|CCL2, Chemokine|CCL2, Chemokines|Chemokine, CCL2|Monocyte Chemoattractant Protein 1|monocyte chemotactic protein-1|MCP1|Monocyte Chemotactic Protein-1|Chemokine CCL2|mcp-1|monocyte chemoattractant protein 1|Chemokine (C-C Motif) Ligand 2|Monocyte Chemotactic Protein 1|Chemokines CCL2|Monocyte Chemotactic and Activating Factor|CCL2 Chemokine | Monocyte Chemoattractant Protein-1 |
C0678812 | null | null | systemic administration |
C1522910 | The process whose specific outcome is the progression of the shoot system over time, from its formation to the mature structure. [GOC:go_curators] | shoot development | shoot system development |
C0056878 | null | cysteine hydrogen sulfite ester|alanine 3-sulfinic acid|cysteinesulfinic acid, (+,-)- | cysteine sulfinic acid |
C0331451 | null | Monocotyledon (organism)|Monocotyledon|Monocotyledon, NOS|monocotyledon|MONOCOTYLEDONS | Monocotyledon |
C0507618 | Wall of cardiac chamber that surrounds the cavity of a ventricle. | ventricles wall|ventricles walls|Ventricular wall|Wall of ventricle|ventricle wall|ventricular wall | Wall of ventricle |
C0036980 | Shock resulting from diminution of cardiac output in heart disease. | heart shocking|Cardiac shock syndrome|shock cardiogenic|shock heart|heart shock|Cardiovascular shock|CARDIOGENIC SHOCK|SHOCK CARDIOGENIC|cardiocirculatory collapse|Shock, cardiogenic|Cardiogenic Shock|Power failure syndrome|cardiogenic shock|Cardiogenic shock (disorder)|Shock, Cardiogenic|Cardiogenic shock | Shock, Cardiogenic |
C0204901 | null | Hemodynamic measurements|Hemodynamic measurements (procedure)|Haemodynamic measurements | Hemodynamic measurements |
C1269893 | null | Entire coronary sinus (body structure)|Entire coronary sinus|Entire CS - Coronary sinus | Entire coronary sinus |
C0008356 | An ENTEROTOXIN from VIBRIO CHOLERAE. It consists of two major protomers, the heavy (H) or A subunit and the B protomer which consists of 5 light (L) or B subunits. The catalytic A subunit is proteolytically cleaved into fragments A1 and A2. The A1 fragment is a MONO(ADP-RIBOSE) TRANSFERASE. The B protomer binds cholera toxin to intestinal epithelial cells, and facilitates the uptake of the A1 fragment. The A1 catalyzed transfer of ADP-RIBOSE to the alpha subunits of heterotrimeric G PROTEINS activates the production of CYCLIC AMP. Increased levels of cyclic AMP are thought to modulate release of fluid and electrolytes from intestinal crypt cells. | Enterotoxin CT, Cholera|Cholera Toxin|CT, Cholera Enterotoxin|Cholera Enterotoxin CT|choleragen|Cholera Exotoxin|Exotoxin, Cholera|Cholera toxin|Toxin, Cholera|cholera toxin|Cholera toxin (substance)|Choleragen | Cholera Toxin |
C0050945 | null | AG 60-99 | AG 60.99 |
C0050945 | null | AG 60-99 | AG 60.99 |
C0050945 | null | AG 60-99 | AG 60.99 |
C1479923 | null | null | Phomopsis camptothecae |
C1479923 | null | null | Phomopsis camptothecae |
C0006670 | null | Calcitonin Gene Related Peptide I|Calcitonin Gene-Related Peptide I | Calcitonin Gene-Related Peptide I |
C1334162 | Immunoglobulin-binding protein 1 (339 aa, ~39 kDa) is encoded by the human IGBP1 gene. This protein plays a role in the modulation of both protein phosphatase activity and B-cell receptor-mediated signaling. | Protein Phosphatase 2/4/6 Regulatory Subunit|CD79a-Binding Protein 1|alpha 4 phosphoprotein, human|IGBP1 protein, human|alpha4 phosphoprotein, human|CD79A-Binding Protein 1|immunoglobulin (CD79A) binding protein 1, human|B Cell Signal Transduction Molecule Alpha 4|Immunoglobulin Binding Protein 1|Tap42 protein, human|B-Cell Signal Transduction Molecule Alpha 4|Protein Alpha-4|Immunoglobulin-Binding Protein 1|Alpha 4 Protein|Renal Carcinoma Antigen NY-REN-16|Alpha 4|IGBP1|Immunoglobulin (CD79A) Binding Protein 1 | IGBP1 protein, human |
C1334162 | Immunoglobulin-binding protein 1 (339 aa, ~39 kDa) is encoded by the human IGBP1 gene. This protein plays a role in the modulation of both protein phosphatase activity and B-cell receptor-mediated signaling. | Protein Phosphatase 2/4/6 Regulatory Subunit|CD79a-Binding Protein 1|alpha 4 phosphoprotein, human|IGBP1 protein, human|alpha4 phosphoprotein, human|CD79A-Binding Protein 1|immunoglobulin (CD79A) binding protein 1, human|B Cell Signal Transduction Molecule Alpha 4|Immunoglobulin Binding Protein 1|Tap42 protein, human|B-Cell Signal Transduction Molecule Alpha 4|Protein Alpha-4|Immunoglobulin-Binding Protein 1|Alpha 4 Protein|Renal Carcinoma Antigen NY-REN-16|Alpha 4|IGBP1|Immunoglobulin (CD79A) Binding Protein 1 | IGBP1 protein, human |
C0281318 | A therapeutic regimen that uses synthetic compounds or natural substances to prevent the development of new blood vessels. | antiangiogenesis therapy|antiangiogenesis|Angiogenesis Inhibition|Antiangiogenesis|Antiangiogenesis Therapy|Anti-Angiogenesis | antiangiogenesis therapy |
C0525038 | The naturally occurring or experimentally induced replacement of one or more AMINO ACIDS in a protein with another. If a functionally equivalent amino acid is substituted, the protein may retain wild-type activity. Substitution may also diminish, enhance, or eliminate protein function. Experimentally induced substitution is often used to study enzyme activities and binding site properties. | Amino Acid Substitutions|Substitution, Amino Acid|Substitutions, Amino Acid | Amino Acid Substitution |
C0559522 | Refers to the genitalia (external and internal sex organs and glands). | Systemata genitalia|genital|Genital system, NOS|Genital|genital organ|Genital structure (body structure)|Reproductive system|Genital structure|Set of genital systems|genital system|Genital (qualifier value)|Genital systems set|urogenital system (genital part)|Genital system|Genital systems | Genital system |
C0024794 | The type species of the genus MARDIVIRUS in the family HERPESVIRIDAE. It is the etiologic agent of MAREK DISEASE, infecting domestic fowl and wild birds. | Marek's disease virus serotype 1 MDV-1|Neurolymphomatosis Virus|Paralysis Virus, Fowl|Gallid herpesvirus 2|Marek disease virus type 1|Marek's Disease Virus Serotype 1|Gallid alphaherpesvirus 2|Marek's disease virus type 1 MDV1|Mareks disease virus|Marek's disease virus|Gallid Herpesvirus 2|Herpesvirus 2, Gallid|Fowl Paralysis Viruses|Fowl Paralysis Virus|Paralysis Viruses, Fowl|Gallid herpesvirus type 2|Neurolymphomatosis Viruses|Marek disease virus|Marek's disease herpesvirus|Herpesvirus 2 (gamma), Gallid|Marek's disease virus MDV1|Marek's disease herpesvirus 1|Marek's disease virus (MDV)|Turkey herpesvirus|Marek's disease virus MDV|Marek Disease Herpesvirus 1|Marek's Disease Herpesvirus 1|Gallid herpesvirus 2 (organism) | Herpesvirus 2, Gallid |
C1413978 | null | DEFENSIN, BETA, 2, FORMERLY|DEFENSIN, BETA, 4A|HBD-2|beta-defensin 2|DEFB-2|HBD2|DEFB4, FORMERLY|SAP1|DEFB4A gene|beta defensin 2|DEFB2, FORMERLY|DEFB4A|DEFENSIN, BETA, 4, FORMERLY|defensin beta 4A|beta defensin-2 | DEFB4A gene |
C1413978 | null | DEFENSIN, BETA, 2, FORMERLY|DEFENSIN, BETA, 4A|HBD-2|beta-defensin 2|DEFB-2|HBD2|DEFB4, FORMERLY|SAP1|DEFB4A gene|beta defensin 2|DEFB2, FORMERLY|DEFB4A|DEFENSIN, BETA, 4, FORMERLY|defensin beta 4A|beta defensin-2 | DEFB4A gene |
C1332399 | This gene is involved in transcriptional repression and plays a role in the modulation of B-cell responses. | LYMPHOMA-ASSOCIATED ZINC FINGER GENE ON CHROMOSOME 3|ZNF51|BCL6 Gene|ZBTB27|BCL6 gene|B-CELL LYMPHOMA 6|BCL5|BCL6A|B-Cell CLL/Lymphoma 6 Gene|ZINC FINGER PROTEIN 51|LAZ3|BCL6 transcription repressor|BCL6 | BCL6 gene |
C1332399 | This gene is involved in transcriptional repression and plays a role in the modulation of B-cell responses. | LYMPHOMA-ASSOCIATED ZINC FINGER GENE ON CHROMOSOME 3|ZNF51|BCL6 Gene|ZBTB27|BCL6 gene|B-CELL LYMPHOMA 6|BCL5|BCL6A|B-Cell CLL/Lymphoma 6 Gene|ZINC FINGER PROTEIN 51|LAZ3|BCL6 transcription repressor|BCL6 | BCL6 gene |
C1314889 | A highly-conserved AAA ATPase that functions in the biogenesis of the transitional ENDOPLASMIC RETICULUM and fragmentation and reassembly of the GOLGI APPARATUS during MITOSIS. It also functions in a complex with UFD1L and NPLOC4 proteins to export misfolded ubiquitinated proteins from the endoplasmic reticulum and outer mitochondrial membrane to the cytoplasm for degradation by the PROTEASOME and also plays a role in AUTOPHAGY of ubiquitinated proteins. It occurs in neuronal INCLUSION BODIES from patients with AMYOTROPHIC LATERAL SCLEROSIS and LEWY BODIES from PARKINSON DISEASE patients. | Valosin Containing Protein|p97 Valosin-Containing Protein|Valosine Containing Protein|Valosin-Containing Protein, p97|CDC48 Protein|p97 Valosin Containing Protein|Cell Cycle Protein CDC48p|Cell Cycle Protein CDC48|Valosin-Containing Protein|Valosine-Containing Protein | valosin-containing protein |
C0744425 | null | null | glucocorticoid therapy |
C0023452 | When the disease process is confined to a mass lesion with no or minimal evidence of blood and less than 25% marrow involvement, the diagnosis is lymphoblastic lymphoma; with blood and greater than 25% marrow involvement, ALL is the appropriate term. | ALL, pediatric|childhood leukemia, acute lymphoblastic|Childhood Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia (ALL)|Childhood Precursor Lymphoblastic Leukemia|pediatric acute lymphoblastic leukemia|childhood acute lymphoid leukemia|Pediatric Acute Lymphocytic Leukemia (ALL)|pediatric all|Childhood ALL|childhood acute lymphoblastic leukemia|Leukemia, Lymphocytic, Acute, L1|pediatric acute lymphogenous leukemia|Pediatric Acute Lymphoblastic Leukemia|childhood all|ALL, childhood|L1 Lymphocytic Leukemia|Leukemia, acute lymphocytic (ALL), child|childhood acute lymphocytic leukemia|ALL, Childhood|lymphoblastic leukemia, acute, childhood|Lymphoblastic Leukemia, Acute, L1|childhood ALL|pediatric acute lymphoid leukemia|pediatric acute lymphocytic leukemia|Lymphoblastic Leukemia, Acute, Childhood|lymphoblastic leukemia, acute, pediatric|Leukemia, Lymphoblastic, Acute, L1|Leukemia, L1 Lymphocytic|Childhood Acute Lymphoid Leukemia|acute lymphoblastic leukemia, pediatric|pediatric ALL|L1 Acute Lymphoblastic Leukemia|leukemia, acute lymphoblastic, pediatric|Lymphocytic Leukemia, L1|childhood precursor lymphoblastic leukemia|acute lymphoblastic leukemia, childhood|leukemia, acute lymphoblastic, childhood|Pediatric ALL|Pediatric Acute Lymphoid Leukemia|childhood acute lymphogenous leukemia | Childhood Acute Lymphoblastic Leukemia |
C0024544 | An enzyme that catalyzes the conversion of (S)-malate and NAD+ to oxaloacetate and NADH. EC 1.1.1.37. | Malate Dehydrogenase|Dehydrogenase, Malic|Malate dehydrogenase|Dehydrogenase, NAD-Malate|Malic Dehydrogenase|NAD-Malate Dehydrogenase|NAD-L-Malate Dehydrogenase|EC 1.1.1.37|MDH|dehydrogenase malate|NAD-Dependent Malic Dehydrogenase|Malate (NAD) Dehydrogenase|malate dehydrogenase|NAD-Dependent Malate Dehydrogenase|Malate dehydrogenase (substance)|NAD-Malic Dehydrogenase|Malic Acid Dehydrogenase|L-Malate Dehydrogenase|NAD-Specific Malate Dehydrogenase|NAD Malate Dehydrogenase|NAD-Linked Malate Dehydrogenase|Malic dehydrogenase|(S)-Malate:NAD+ oxidoreductase|Dehydrogenase, Malate|Malate dehydrogenase, NOS | Malate Dehydrogenase |
C0680398 | null | null | secondary group |
C0872285 | null | therapeutic protein|protein therapeutics|proteins therapeutic|protein therapeutic | therapeutic protein |
C0032302 | Interstitial pneumonia caused by extensive infection of the lungs (LUNG) and BRONCHI, particularly the lower lobes of the lungs, by MYCOPLASMA PNEUMONIAE in humans. In SHEEP, it is caused by MYCOPLASMA OVIPNEUMONIAE. In CATTLE, it may be caused by MYCOPLASMA DISPAR. | Mycoplasma Pneumonia|Pneumonias, Mycoplasma|Mycoplasma pneumonia|Infection by PPLO|PNEUMONIA, MYCOPLASMAL|Endemic pneumonia|Pneumonias, Primary Atypical|PAP due to Mycoplasma pneumoniae|Mycoplasmal pneumonia|Pneumonia caused by Mycoplasma pneumoniae (disorder)|MYCOPLASMA PNEUMONIA|pneumonia mycoplasma|Pneumonia, Mycoplasma|PPLO|Mycoplasmal Pneumonia|primary atypical pneumonia|cold agglutinin positive pneumonia|Pneumonia, Primary Atypical|Pneumonia caused by Genus Mycoplasma (disorder)|PNEUMONIA, EATON AGENT|Pneumonia caused by PPLO|Eaton agent pneumonia|Pneumonia due to Eaton's agent|Mycoplasma pneumoniae pneumonia|Primary Atypical Pneumonias|Mycoplasma Pneumonias|Atypical Pneumonias, Primary|mycoplasmal pneumonia|Pneumonia due to Mycoplasma pneumoniae|Primary atypical pneumonia caused by Mycoplasma pneumoniae|mycoplasmas pneumonia|PNEUMONIA, COLD AGGLUTININ POSITIVE|mycoplasma pneumonia|Eaton's agent pneumonia|PAP caused by Mycoplasma pneumoniae|Primary Atypical Pneumonia|Primary atypical pneumonia (PAP) due to mycoplasma|PNEUMONIA, PRIMARY ATYPICAL|Pneumonia due to PPLO|Primary atypical pneumonia due to Mycoplasma pneumoniae|Pneumonia due to mycoplasma pneumoniae|Atypical Pneumonia, Primary|pplo|Pneumonia caused by Mycoplasma pneumoniae | Mycoplasma pneumonia |
C1150095 | Catalysis of the hydrolysis of a peptide bond. A peptide bond is a covalent bond formed when the carbon atom from the carboxyl group of one amino acid shares electrons with the nitrogen atom from the amino group of a second amino acid. [GOC:jl, ISBN:0815332181] | hydrolase, acting on peptide bonds|proteinase activity|peptidase activity|proteinase|peptide hydrolase activity|protease activity | peptidase activity |
C0022568 | Inflammation of the cornea. | INFLAMMATION CORNEAL|KERATITIS|corneal inflammation|Inflammation of cornea|Unspecified keratitis|Keratitis, NOS|Corneal inflammation|Keratitides|CORNEAL INFLAMMATION|Keratitis (disorder)|Corneal keratitis|Cornea inflamed|keratitis|Keratitis | Keratitis |
C0338426 | null | Amebic encephalitis (disorder)|amebic encephalitis|Amoebic encephalitis|amoebic encephalitis | Amebic encephalitis |
C0996862 | Plant genus in the pea family (Fabaceae). | Vigna|Cowpeas|Cowpea | Vigna |
C0044091 | null | Thienyl cyclohexylpiperidine|((Thienyl-2)-1 cyclohexyle)-N piperidine|1-(1-(2-thienyl)cyclohexyl)piperidine|TENOCYCLIDINE|thienylcyclohexylpiperidine|1-(1-(2-thienyl) cyclohexyl) piperidine (substance)|N-(1-(2-thiophenyl)cyclohexyl)piperidine|1-(1-(2-Thienyl) cyclohexyl) piperidine|1-[1-(thiophen-2-yl)cyclohexyl]piperidine|1-(1-(2-thienyl) cyclohexyl) piperidine|tenocyclidine-TCP|TCP|Tenocyclidine|Tenocyclidinum|tenocyclidine|tcp|Tenociclidina|thienyl cyclohexylpiperidine|2-thienylphencyclidine|1-(1-(2-Thienyl)cyclohexyl)piperidine | tenocyclidine |
C0043137 | null | Wheat product (substance)|Wheat|wheat|Wheat (substance)|Wheat product|WHEAT | Wheat (Dietary) |
C0085611 | An electrocardiographic finding of an atypical cardiac rhythm resulting from a pathologic process in the cardiac atria. | Atrial Arrhythmia by EKG Finding|Atrial Arrhythmia|Atrial arrhythmias|ARRHYTHMIA ATRIAL|Arrhythmia, atrial|atrial arrhythmia|ATRIAL ARRHYTHMIA|arrhythmias atrial|Atrial Arrhythmia by ECG Finding|atrial ectopy|Arrhythmia, Atrial|arrhythmia atrial|Atrial arrhythmia (disorder)|atrial dysrhythmias|Atrial arrhythmia|ARRHYTHMIA ATRIAL (NOS)|Atrial arrhythmia, NOS | Atrial arrhythmia |
C0232202 | An electrocardiographic finding of an atrial rhythm which originates from the sinoatrial node that is considered normal for the population. There are no extra beats or conduction abnormalities. (CDISC) | normal sinus rhythm|Cardiac rhythm, normal|normal heart sinus rhythm|NORMAL SINUS RHYTHM|normal rhythms sinus|Normal Sinus Rhythm|Normal sinoatrial rhythm|Normal cardiac rhythm|Normal sinus rhythm|Normal sinus rhythm (finding)|normal rhythm sinus | Normal sinus rhythm |
C1619966 | A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes. | ABATACEPT|Abatacept|Abatacept (substance)|Abatacept recombinant|Product containing abatacept (medicinal product)|Abatacept-containing product|abatacept | abatacept |
C1619966 | A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes. | ABATACEPT|Abatacept|Abatacept (substance)|Abatacept recombinant|Product containing abatacept (medicinal product)|Abatacept-containing product|abatacept | abatacept |
C1450533 | A cholesteryl ester transfer protein (CETP) inhibitor that reduces the heterotypic transfer of cholesteryl ester from HDL to LDL and/or VLDL. Torcetrapib failed in phase III trials due to excess deaths. | TORCETRAPIB|Torcetrapib|(2R,4S)-4-((3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic Acid Ethyl Ester | torcetrapib |
C0039538 | A true neoplasm composed of a number of different types of tissue, none of which is native to the area in which it occurs. It is composed of tissues that are derived from three germinal layers, the endoderm, mesoderm, and ectoderm. They are classified histologically as mature (benign) or immature (malignant). (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1642) | Teratoma|Teratoid Tumors|teratoid tumor|TERATOMA|Tumors, Teratoid|Teratoma, NOS|Teratoma, no International Classification of Diseases for Oncology subtype|Teratomas|Tumor, Teratoid|Dysembryomas|Teratoma, no International Classification of Diseases for Oncology subtype (morphologic abnormality)|Teratoma, no ICD-O subtype|teratoid tumors|Teratoid Tumor|teratoma|Dysembryoma|Teratoma (disorder)|teratomas | Teratoma |
C0011957 | Organic chemicals which have two amino groups in an aliphatic chain. | Diamine|diamine|Diamine (substance) | Diamines |
C0011882 | Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325) | Diabetic neuropathy|Neuropathies, Diabetic|Diabetic Neuropathies|NEUROPATHY, DIABETIC|Neuropathy, Diabetic|diabetic nerve damage|Neuropathy due to diabetes mellitus|DIABETIC NEUROPATHY|Diabetic neuropathies|diabetic neuropathies|diabetic neuropathy|Diabetes with neurological manifestations|Neuropathy due to diabetes mellitus (disorder)|Diabetes mellitus with neuropathy|Neuropathy, diabetic|Diabetic Neuropathy | Diabetic Neuropathies |
C0600548 | An inbred strain of Long-Evans rats that develops hyperglycemia, hyperinsulinemia, and mild obesity, mostly in males, that resembles non-insulin-dependent diabetes mellitus in humans. It was developed from outbred Long-Evans stock in 1983. | Inbred OLETF Rat|Otsuka-Long-Evans-Tokushima Fatty Rats|OLETF Rat, Inbred|OLETF Rats|Rat, OLETF|Otsuka Long Evans Tokushima Rats|Rats, OLETF|Rats, Otsuka-Long-Evans-Tokushima Fatty|Rat, Inbred OLETF|Otsuka-Long-Evans-Tokushima Rats|Otsuka Long Evans Tokushima Fatty Rats|Fatty Rats, Otsuka-Long-Evans-Tokushima|OLETF Rats, Inbred|OLETF Rat|Rats, Otsuka-Long-Evans-Tokushima|Inbred OLETF Rats | Rats, Inbred OLETF |
C0324537 | An outbred strain of rats developed in 1915 by crossing several Wistar Institute white females with a wild gray male. Inbred strains have been derived from this original outbred strain, including Long-Evans cinnamon rats (RATS, INBRED LEC) and Otsuka-Long-Evans-Tokushima Fatty rats (RATS, INBRED OLETF), which are models for Wilson's disease and non-insulin dependent diabetes mellitus, respectively. | Evans Rats, Long|long evans rats|Long-Evans rat|Long Evans rat|Long Evans Rats|Rats, Long Evans|Long-Evans Rats|Long Evans rat (organism) | Rats, Long-Evans |
C0079365 | Fluoroimmunoassay where detection of the hapten-antibody reaction is based on measurement of the increased polarization of fluorescence-labeled hapten when it is combined with antibody. The assay is very useful for the measurement of small haptenic antigens such as drugs at low concentrations. | Immunoassays, Fluorescence Polarization|Immunoassay, Fluorescence Polarization|Fluorescence polarisation immunoassay|Polarization Fluoroimmunoassay|Fluoroimmunoassays, Polarization|Fluorescence polarization immunoassay (FPIA)|Fluorescence polarization immunoassay technique|Polarization Fluoroimmunoassays|Fluorescence polarization immunoassay (procedure)|Polarization Immunoassays, Fluorescence|Fluorescence polarization immunoassay technique (qualifier value)|Fluoroimmunoassay, Polarization|Fluorescence polarisation immunoassay technique|Fluorescence polarization immunoassay, NOS|Fluorescence Polarization Immunoassays|Fluorescence polarization immunoassay|Polarization Immunoassay, Fluorescence | Fluorescence Polarization Immunoassay |
C1373177 | null | Intestinal Metabolism [PK] | Intestinal Metabolism |
C0288171 | A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease. | IRBESARTAN|Irbesartan (substance)|Irbesartan-containing product|irbesartan|2-N-Butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one|Product containing irbesartan (medicinal product)|2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one|1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-|Irbesartan | irbesartan |
C0288171 | A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease. | IRBESARTAN|Irbesartan (substance)|Irbesartan-containing product|irbesartan|2-N-Butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one|Product containing irbesartan (medicinal product)|2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one|1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-|Irbesartan | irbesartan |
C0065162 | A synthetic broad-spectrum fluoroquinolone with antibacterial activity. Lomefloxacin inhibits DNA gyrase, a type II topoisomerase involved in the induction or relaxation of supercoiling during DNA replication. This inhibition leads to a decrease in DNA synthesis during bacterial replication, resulting in cell growth inhibition and eventually cell lysis. | (±)-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid|1,4-Dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid|lomefloxacin|LFLX|Lomefloxacino|Lomefloxacin (substance)|3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-, monohydrochloride|1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid|Lomefloxacin-containing product|Lomefloxacin|Product containing lomefloxacin (medicinal product)|lomenfloxacin|LOMEFLOXACIN|Lomefloxacine|Lomefloxacinum | lomefloxacin |
C1533585 | A gene made by joining parts of two different genes. Fusion genes may occur naturally in the body by transfer of DNA between chromosomes. For example, the BCR-ABL gene found in some types of leukemia is a fusion gene. Fusion genes can also be made in the laboratory by combining genes or parts of genes from the same or different organisms. | fusion gene|Fusion Gene | Fusion Gene |
C1157706 | The chemical reactions and pathways resulting in the formation of butyrate, the anion of butyric acid. [ISBN:0198506732] | butanoic acid anabolism|butyrate anabolism|butyrate formation|butyrate synthesis|butanoic acid formation|butanoic acid biosynthetic process|butanoic acid biosynthesis|butanoic acid synthesis|butyrate biosynthesis | butyrate biosynthetic process |
C1565434 | A family of non-receptor, PROLINE-rich protein-tyrosine kinases. | Focal Adhesion Kinase|Focal Adhesion Protein Tyrosine Kinases|Focal Adhesion Protein Tyrosine Kinase Family|Focal Adhesion Protein-Tyrosine Kinase Family|Focal adhesion kinase|Focal Adhesion Protein-Tyrosine Kinase|Focal Adhesion Protein-Tyrosine Kinases | Focal Adhesion Protein-Tyrosine Kinases |
C0009325 | A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH). | Collagens|Collagen (substance)|Collagen|collagen|Collagen-containing product|Product containing collagen (medicinal product)|collagens | collagen |
C1278837 | null | Entire cervical spinal cord|Entire cervical spinal cord (body structure) | Entire cervical spinal cord |
C0051441 | null | 7,8-benzoflavone | alpha-naphthoflavone |
C0178735 | very large molecule having a polymeric chain structure as in proteins, polysaccharides, DNA, and other natural and synthetic polymers. | macromolecule|macromolecules|Macromolecules | macromolecule |
C0063765 | A derivative of ACETIC ACID that contains one IODINE atom attached to its methyl group. | Acetic acid, iodo-|Acid, Iodoacetic|Monoiodoacetic Acid|Acid, Monoiodoacetic | Iodoacetic Acid |
C0016053 | A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95) | RHEUMATISM, TENSION|Fibromyalgias|Myofascial Pain Syndrome, Diffuse|Fibrositides|Fibromyositis Fibromyalgia Syndrome|Diffuse Myofascial Pain Syndrome|FIBROSITIS|FIBROMYOSITIS|Fibrositis (disorder)|fibromyalgia (FM)|MPD syndrome|MPS - myofascial pain syndrome|fibromyositis fibromyalgia syndrome|Rheumatism, Muscular|Myofascial pain syndrome (disorder)|Fibromyalgia-Fibromyositis Syndrome|syndrome fibromyalgia|Fibromyalgia|fibromyalgia (FMS)|fibromyalgia syndrome|Syndromes, Fibromyalgia-Fibromyositis|Fibro|fibrositis|Syndrome, Fibromyositis-Fibromyalgia|fms|myofascial pain dysfunction syndrome|fibromyalgias|Fibromyalgia, NOS|FIBROMYALGIA|FMS|Fibromyositis-Fibromyalgia Syndrome|mpd syndrome|Fibrositis, NOS|Myofascial pain syndrome|Fibromyositis NOS|pain syndrome myofascial|Fibromyalgia Fibromyositis Syndrome|Fibromyositis-Fibromyalgia Syndromes|Muscular rheumatism (disorder)|Syndrome, Fibromyalgia-Fibromyositis|Fibromyositis|fibromyositis|Myofascial trigger point syndrome|Fibromyalgia (disorder)|Fibrositis|Fibromyositis, NOS|Myofascial pain dysfunction syndrome|Fibromyositis (disorder)|Muscular Rheumatism|Fibromyalgia Syndrome|muscular rheumatism|Muscular rheumatism|Fibromyalgia-Fibromyositis Syndromes|fibromyalgia|Syndromes, Fibromyositis-Fibromyalgia | Fibromyalgia |
C0338908 | null | anxiety with depression|anxiety depression|Mixed anxiety and depressive disorder (disorder)|Depression with anxiety|mixed anxiety depression|Anxiety depression|depression with anxiety|anxiety depression mixed|depression anxiety | Mixed anxiety and depressive disorder |
C0009782 | A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides. | DISEASES OF THE CONNECTIVE TISSUES|Tissue Disease, Connective|Disorder of Connective Tissue|Connective Tissue Disorder|CONNECTIVE TISSUE DISEASE|Disorder of connective tissue (disorder)|connective tissue disorder diagnosis|Connective Tissue Disorders|connective tissue diseases|Connective tissue disease or syndrome|connective tissue disease|Primary Disorder of Connective Tissue|connective tissue disorder|Connective tissue disease|connective tissue disorders|Diseases, Connective Tissue|Disorder of connective tissue|Connective Tissue Diseases|Diseases and Syndromes of Connective Tissue|Connective Tissue Disease|Disease, Connective Tissue|Connective tissues--Diseases | Connective Tissue Diseases |
C0020550 | Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE. | Hyperthyroidism (disorder)|hyperthyroid|Hyperthyroidism|Hyperthyroidism, NOS|HYPERTHYROIDISM|Hyperthyroid|hyperthyroidism|Overactive thyroid|hyperthyroidism nos|overactive thyroid|Overactive Thyroid|Hyperthyroids|Hyperthyroidism NOS | Hyperthyroidism |
C0238143 | Inflammation of a specific segment of glomeruli, which is associated with subacute bacterial endocarditis, and frequently produces microscopic hematuria without azotemia. | GLOMERULONEPHRITIS, FOCAL PROLIFERATIVE|GLOMERULONEPHRITIS, LOCAL|GLOMERULONEPHRITIS, FOCAL EMBOLIC | Focal Embolic Glomerulonephritis |
C0011633 | A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6) | DERMATOMUCOSOMYOSITIS|Polymyositis-Dermatomyositis|dermatomyositides|Dermatomyositis|WAGNER-UNVERRICHT SYNDROME|Polymyositis Dermatomyositis|Polymyositis with skin involvement|dermatopolymyositis|DERMATOMYOSITIS|Dermatomyositis (disorder)|dermatomyositis|POLYMYOSITIS/DERMATOMYOSITIS|Dermatopolymyositis|DM - Dermatomyositis|POLYMYOSITIS DERMATOMYOSITIS|Wagner-Unverricht syndrome | Dermatomyositis |
C0221238 | A focal inflammation of glomeruli secondary to mesangial cell proliferation and matrix deposition within the mesangium. | GLOMERULONEPHRITIS, MESANGIAL PROLIFERATIVE|Glomerulonephritis, mesangial proliferative|Mesangial proliferative glomerulonephritis (disorder)|Mesangial Proliferative Glomerulonephritis|Mesangial proliferative glomerulonephritis | Mesangial proliferative glomerulonephritis |
C0017665 | A type of glomerulonephritis that is characterized by the accumulation of immune deposits (COMPLEMENT MEMBRANE ATTACK COMPLEX) on the outer aspect of the GLOMERULAR BASEMENT MEMBRANE. It progresses from subepithelial dense deposits, to basement membrane reaction and eventual thickening of the basement membrane. | Membranous glomerulonephritis|Nephropathy, Membranous|Glomerulopathy, Membranous|membranous glomerulonephritis|Membranous Glomerulonephropathy|Glomerulonephropathy, Membranous|Membranous nephropathy NOS|Membranous Glomerulonephritides|Membranous glomerulonephritis (disorder)|NEPHROPATHY, MEMBRANOUS|Membranous Glomerulopathy|Membranous nephropathy|membranous glomerulopathy|Extramembranous Glomerulopathy|glomerulonephritis membranous|Glomerulopathy, Extramembranous|membranous nephropathy|membranous glomerulonephropathy|Membranous Glomerulonephritis|mgn|GLOMERULONEPHRITIS, MEMBRANOUS|Glomerulonephritides, Membranous|Membranous Nephropathy|MGN - Membranous glomerulonephritis|Membranous glomerulonephropathy|Membranous glomerulonephritis NOS|Glomerulonephritis, Membranous|MEMBRANOUS GLOMERULOPATHY|Chronic nephritic syndrome, diffuse membranous glomerulonephritis|GLOMERULOPATHY, MEMBRANOUS | Membranous glomerulonephritis |
C1335439 | Encoded by Polymerase Genes, Polymerase enzymes catalyze polymerization reactions, especially of nucleotides to polynucleotides. (NCI) | null | Polymerase |
C0041228 | A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces "African sleeping sickness." Nagana is a rapidly fatal trypanosomiasis of horses and other animals. | Sleeping sickness NOS|African Trypanosomiasis|Sleeping sickness, NOS|SCHLAFKRANKHEIT|TRYPANOSOMIASIS, AFRICAN|African Trypanosomiases|African Sleeping Sickness|Sicknesses, African Sleeping|African trypanosomiasis|Trypanosomiases, African|African trypanosomiasis (disorder)|African trypanosomiasis, unspecified|African sleeping sickness|MALADIE DU SOMMEIL|Sickness, African Sleeping|Sleeping Sicknesses, African|sleeping sickness|African sickness sleeping|Sleeping sickness|Sleeping Sickness, African|Sleeping Sickness|SLEEPING SICKNESS, AFRICAN|SLEEPING SICKNESS|Trypanosomiasis, African|African Sleeping Sicknesses|sickness sleeping | African Trypanosomiasis |
C0585171 | null | Protozoan parasite, NOS|protozoan parasite|parasites protozoan|Parasite, protozoan|Protozoan parasite (navigational concept)|Protozoal parasite | Protozoan parasite |
C0041232 | Trypanosomiasis caused by infection by Trypanosoma brucei gambiense. | Trypanosomiasis, Gambian|Gambiense trypanosomiasis infection|Infection caused by Trypanosoma gambiense (disorder)|Chronic sleeping sickness|Gambian Trypanosomiasis|Gambian sleeping sickness|Infection caused by Trypanosoma gambiense|Infection by Trypanosoma gambiense|Gambian trypanosomiasis | Infection by Trypanosoma gambiense |
C0025217 | Arsenical used in trypanosomiases. It may cause fatal encephalopathy and other undesirable side effects. | Melarsoprol-containing product|melarsoprol|1,3,2-Dithiarsolane-4-methanol, 2-(4-((4,6-diamino-1,3,5-triazin-2-yl)amino)phenyl)-|Melarsoprol (substance)|Melarsoprol|Product containing melarsoprol (medicinal product) | Melarsoprol |
C0025217 | Arsenical used in trypanosomiases. It may cause fatal encephalopathy and other undesirable side effects. | Melarsoprol-containing product|melarsoprol|1,3,2-Dithiarsolane-4-methanol, 2-(4-((4,6-diamino-1,3,5-triazin-2-yl)amino)phenyl)-|Melarsoprol (substance)|Melarsoprol|Product containing melarsoprol (medicinal product) | Melarsoprol |
C0002260 | An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway. | eflornithine|2-(Difluoromethyl)-DL-ornithine|Ornithine, 2-(difluoromethyl)-|2-Difluoromethylornithine|DL-alpha-Difluoromethylornithine|Difluromethylornithine|Product containing eflornithine (medicinal product)|Alpha-Difluoromethylornithine|D,L-alpha-Difluoromethylornithine|Eflornithine-containing product|alpha-difluoromethylornithine|DL alpha Difluoromethylornithine|alpha-Difluoromethyl Ornithine|2-(difluoromethyl)ornithine|DFMO|alpha Difluoromethylornithine|alpha-Difluoromethylornithine|Eflornithine|α-difluoromethylornithine|(RS)-2,5-diamino-2-(difluoromethyl)pentanoic acid|difluoromethylornithine|alpha Difluoromethyl Ornithine|Difluoromethylornithine|Eflornithine (substance)|dfmo|difluoromethylornithine (DFMO)|EFLORNITHINE|Ornithine, alpha-Difluoromethyl | eflornithine |
C0549113 | The portion of the ascending aorta between the aortic annulus and the sinotubular junction. | ASCENDING AORTA, AORTIC ROOT|Supraaortic valve area|Bulb of aorta|Aortic root|Aortic Root|Root of aorta|Aortic bulb|aortic root|Bulb of ascending aorta|Bulbus aortae|Supra-aortic valve area|root aortic|Supraaortic valve area structure (body structure) | Supraaortic valve area structure |
C0152101 | A condition caused by underdevelopment of the whole left half of the heart. It is characterized by hypoplasia of the left cardiac chambers (HEART ATRIUM; HEART VENTRICLE), the AORTA, the AORTIC VALVE, and the MITRAL VALVE. Severe symptoms appear in early infancy when DUCTUS ARTERIOSUS closes. | Hypoplasia of left heart|left hypoplastic heart|hypoplasia left heart|HLH - Hypoplastic left heart syndrome|Hypoplastic left heart syndrome|hypoplastic left heart syndrome|heart hypoplastic left|Left Heart Hypoplasia Syndrome|Hypoplastic Left Heart Syndrome|left heart hypoplastic|HYPOPLASTIC LEFT HEART|HLHS - Hypoplastic left heart syndrome|Hypoplastic left heart syndrome (disorder)|Left Heart Syndrome, Hypoplastic|hypoplastic left heart|heart hypoplastic left syndrome|Underdeveloped left heart|Hypoplastic left heart | Hypoplastic Left Heart Syndrome |
C0152424 | An umbrella term used to describe several very different complex congenital heart defects that share the same problem: the heart has only one functional ventricle (anatomically right or left or indeterminate) supplying the systemic circulation. These defects include tricuspid atresia, hypoplastic left or right heart syndrome, double outlet right ventricle, double inlet left ventricle, and other forms of single ventricle defects. | Single ventricle|Common ventricle|Absence of interventricular septum (single ventricle)|ventricle common|Cor triloculare biatriatum|univentricular heart|Univentricular Heart|Common Ventricle|Absence of interventricular septum|Complex Single Ventricle|Univentricular Hearts|Common Ventricle Disorder|cor triloculare biatriatum|single ventricle|Ventricle, Complex Single|Complex Single Ventricles|Common ventricle (disorder) | Common ventricle |
C0226501 | null | Structure of muscular type vein|Muscular type vein|Large vein|Structure of muscular type vein (body structure) | Structure of muscular type vein |
C0018795 | Procedures in which placement of CARDIAC CATHETERS is performed for therapeutic or diagnostic procedures. | heart catheterization procedure|cardiac catheterisation|Cardiac catheterization procedure, NOS|CARDIAC CATHETERIZATION|Catheterization, Heart|Cardiac catheterization procedure|Cardiac Catheterization Procedures|Heart Catheterization|CCA - Cardiac catheterisation|Heart Catheterizations|Cardiac catheterisation procedure|Cardiac catheterisation|cardiac catheterization|Cardiac catheterization|Insertion of catheter into heart chamber, NOS|Cardiac Catheterization|cardiac catheterizations|Cardiac Catheterizations|Cardiac catheterization NOS|Insertion of catheter into heart chamber|CCA - Cardiac catheterization|heart catheterization|Catheterization, Cardiac|Catheterizations, Heart|Cardiac catheterization, NOS|Catheterizations, Cardiac|Cardiac catheterization (procedure) | Cardiac Catheterization Procedures |
C1267474 | null | Entire left hepatic veins|Entire left hepatic vein (body structure)|Entire left hepatic vein | Entire left hepatic vein |
C0031046 | Inflammation of the PERICARDIUM from various origins, such as infection, neoplasm, autoimmune process, injuries, or drug-induced. Pericarditis usually leads to PERICARDIAL EFFUSION, or CONSTRICTIVE PERICARDITIS. | Pericarditis, NOS|Pericarditis|PERICARDITIS|pericarditis|Pericarditis (disorder)|Swelling or irritation of membrane around heart|Pericarditis NOS|an inflammation of the membrane surrounding the heart | Pericarditis |
C0031042 | Surgical excision (total or partial) of a portion of the pericardium. Pericardiotomy refers to incision of the pericardium. | Pericardiectomy|Pericardiectomies|Pericardiectomy, NOS|pericardiectomy|Pericardectomy|pericardectomy|Pericardiectomy (procedure)|PERICARDIUM: EXCISIONS|Pericardectomies|Excision of pericardium|Excision of Pericardium | Pericardiectomy |
C0850292 | A procedure that uses radio waves to heat and destroy abnormal cells. The radio waves travel through electrodes (small devices that carry electricity). Radiofrequency ablation may be used to treat cancer and other conditions. | Radiofrequency Interstitial Ablation|ablation radiofrequency|Radiofrequency ablation|Radio-Frequency Ablation|Ablation, Radio Frequency|RFA|Radio Frequency Ablation|Ablation, Radio-Frequency|Ablation, Radiofrequency|radiofrequency ablation|Radiofrequency Ablation | Radiofrequency Ablation |
C0155773 | The formation of a blood clot (thrombus) in the portal vein. | PVT - Portal vein thrombosis|Portal vein thrombosis (disorder)|Portal vein thrombosis|pylethrombosis|thrombosis portal vein|portal thrombosis vein|Portal Vein Thrombosis|Thrombosis of the portal vein|portal vein thrombosis|THROMBOSIS, PORTAL VEIN|Deep vein thrombosis of portal vein|Blood clot in portal vein|portal thrombosis | Portal Vein Thrombosis |
C1002427 | null | null | Ostrinia |
C0036679 | null | Separation|Diastasis|Separation (morphologic abnormality)|Separation, NOS|diastasis|separation|Physical detachment | Diastasis |
C0018246 | The external junctural region between the lower part of the abdomen and the thigh. | groins|inguinal|Inguinal|Inguinal region structure|INGUINAL REGIONS|INGUINAL REGION|Inguinal region|inguen|inguinal region|Inguinal region structure (body structure)|Inguen|Inguinal Region|Groin|Inguinal (qualifier value)|Inguinal region, NOS|groin|Groins | Inguinal region |
C1527075 | An act of alteration involving reconsideration and modification. | Revision procedure (qualifier value)|Revision procedure|Revised|Revision|Revise | Revision procedure |
C0682690 | null | null | primary sensory neuron |
C0224306 | null | Longissimus|Musculus longissimus|Structure of longissimus muscle (body structure)|Longissimus muscle|Structure of longissimus muscle|Longissimus muscle, NOS | Longissimus |
C0501385 | sensory nerves bringing impulses toward the central nervous system. | nerve sensory|Sensory nerve|nerves sensory|afferent nerve|sensory nerve|afferent nerves|Nervus sensorius | Sensory nerve |
C0009079 | A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. | Product containing clozapine (medicinal product)|5H-Dibenzo(b,e)(1,4)diazepine, 8-chloro-11-(4-methyl-1-piperazinyl)-|CLOZAPINE|Clozapinum|CLOZAPINE (SANDOZ)|CLOZAPINE (GOLDEN STATE)|Clozapin|Clozapine (substance)|8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine|Clozapine|CLOZAPINE (MAYNE)|Clozapine-containing product|clozapine|Clozapina|cloZAPine | clozapine |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.